Economic and Policy Justification for Public Health Surveillance

Principles & Practice of Public Health Surveillance

Volumn , Issue , 2010, Pages

  Rein, David B ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

Economics; Externality; Market; Policy; Public good; Public health; Surveillance

Indexed keywords

EID: 80053561487     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195372922.003.0003     Document Type: Chapter

References (35)

1. Bourne A. Making the business case for restructuring. People Manag 2008;14(25):41.
2. Office of Management and Budget. What constitutes strong evidence of a program's effectiveness? . Accessed February 13, 2009.
3. U.S. General Accounting Office. Global health: Challenges in improving infectious disease surveillance systems. Washington, DC: U.S. General Accounting Office; 2001. GAO-01-722. 2001. Accessed February 12, 2009.
4. Groseclose S. Evaluation of public health surveillance systems. In: Lee LM, St. Louis ME, Thacker SB, ed. Principles and Practice of Public Health Surveillance, 3rd ed. New York, NY: Oxford University Press; 2009.
5. Thacker S, Berkelman R. History of public health surveillance. In: Halperin W, Baker E, eds. Public Health Surveillance. New York, NY: Van Nostrand Reinhold; 1992: 1-12.
6. Langmuir A. The surveillance of communicable diseases of national importance. N Engl J Med 1963; 268:182-192.
7. Garcia-Abreu A, Halperin W, Danel I. Public Health Surveillance Toolkit: A Guide for Busy Task Managers. Washington, DC: The World Bank; 2002.
8. Krumkamp R, Duerr HP, Reintjes R, Ahmad A, Kassen A, Eichner M. Impact of public health interventions in controlling the spread of SARS: Modelling of intervention scenarios. Int J Hyg Environ Health 2009;212(1):67-75.
9. Lee SH. The SARS epidemic in Hong Kong-a human calamity in the 21st century. Methods Inf Med 2005;44(2):293-298.
10. McNabb SJ, Jajosky RA, Hall-Baker PA, et al. Summary of notifiable diseases-United States, 2006. MMWR 2008;55(53):1-92.
11. Leads from the MMWR. Surveillance of hemophilia-associated acquired immunodeficiency syndrome. JAMA 1986;256(23):3205-3206.
12. Holtgrave DR. Estimating the effectiveness and efficiency of US HIV prevention efforts using scenario and cost-effectiveness analysis. AIDS 2002;16(17):2347-2349.
13. Rein DB, Honeycutt AA, Rojas-Smith L, Hersey JC. Impact of the CDC's section 317 immunization grants program funding on childhood vaccination coverage. Am J Public Health 2006;96(9):1548-1553.
14. Chesson HW. Estimated effectiveness and cost-effectiveness of federally funded prevention efforts on gonorrhea rates in the United States, 1971-2003, under various assumptions about the impact of prevention funding. Sex Transm Dis 2006;33(10 suppl):S140-S144.
15. Amin W, Parwani AV, Schmandt L, et al. National Mesothelioma Virtual Bank: A standard based biospecimen and clinical data resource to enhance translational research. BMC Cancer 2008;8:236. doi 10.1186/1471-2407-8-236.
16. Thacker S, Berkelman R. Public health surveillance in the United States. Epidemiol Rev 1988; 10:164-190.
17. Weiss C. Evaluation: Methods for Studying Programs and Policies, 2nd ed. Upper Saddle River, NJ: Prentice Hall; 1998.
18. Shaddish WJ, Cook T, Leviton L, Carol H. Weiss: Linking evaluation to policy research. In: Foundations of Program Evaluation: Theories of Practice. Newbury Park, CA: Sage Publications; 1995:179-224.
19. Bator FM. The anatomy of market failure. Quarterly J Econ 1958;72(3):351-379.
20. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against influenzarelated illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005;23(13):1540-1548.
21. Galvani AP, Reluga TC, Chapman GB. Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Proc Natl Acad Sci 2007;104(13):5692-5697.
22. Musgrave RA, Musgrave PB. Public Finance in Theory and Practice, 4th ed. New York, NY: McGraw-Hill; 1984.
23. Adamson DM, Chang S, Hansen LG. Health research data for the real world: The MarketScan databases; 2008. . Accessed March 3, 2009.
24. Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002;109(5):839-845.
25. Armstrong GL, Mast EE, Wojczynski M, Margolis HS. Childhood hepatitis B virus infections in the United States before hepatitis B immunization. Pediatrics 2001;108(5):1123-1128.
26. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144(10):705-714.
27. Fidler DP, Gostin LO, Markel H. Through the quarantine looking glass: drug-resistant tuberculosis and public health governance, law, and ethics. J Law Med Ethics 2007;35(4):616-628.
28. Gersovitz M, Hammer JS. The Economic Control of Infectious Diseases. Policy Research Working Paper Series 2607. Geneva, Switzerland: The World Bank; 2001.
29. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007;370(9603):1929-1938.
30. Finlay JE. The Role of Health in Economic Development. Program on the global demography of aging working paper. Cambridge, MA: Harvard University; 2007.
31. Williamson O. Why law, economics, and organization? Ann Rev Law Social Sci 2005;1:369-396.
32. Buchanan JM, Tullock G. The Calculus of Consent, Logical Foundations of Constitutional Democracy. Ann Arbor, MI: University of Michigan Press; 1962.
33. Bozeman B. Public-value failure: When efficient markets may not do. Pub Admin Rev 2002;62(2):145-161.
34. Okun A. Equality and Efficiency, The Big Tradeoff. Washington, DC: The Brookings Institution; 1975.
35. Shiller RJ. From efficient markets theory to behavioral finance. J Econ Perspect 2003;17(1):83-104.